Re: Laurence Albiges, Tom Powles, Michael Staehler, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma. Eur Urol 2019;76:151-6: Active Surveillance in Metastatic Renal Cell Cancer: Missing a Chance for Cure?

Affiliations

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address: a.vanderveldt@erasmusmc.nl.

Comment

Karlijn de Joode et al. Eur Urol. 2020 Mar.

. 2020 Mar;77(3):e76-e77.

doi: 10.1016/j.eururo.2019.09.030. Epub 2019 Oct 12.

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands. Electronic address: a.vanderveldt@erasmusmc.nl.

No abstract available

Comment on

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.
Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A. Albiges L, et al. Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022. Eur Urol. 2019. PMID: 31151678